Tags

Type your tag names separated by a space and hit enter

Ingenol mebutate for the management of cryotherapy-resistant anogenital warts.
Dermatol Ther. 2020 Jun 30 [Online ahead of print]DT

Abstract

Ingenol mebutate (IM), as an active compound, is derived from the sap of the Euphorbia peplus, which is an FDA-approved plant for the treatment of actinic keratosis. Some reports have demonstrated that the IM gel 0.05% is safe and effective in the treatment of external anogenital warts (AGWs) but the efficacy of the drug on the recalcitrant AGWs is not clear. This article assesses the efficacy and safety of the IM gel 0.05% for cryotherapy -resistant AGWs. Totally, 15 cryotherapy-resistant patients with AGWs (including 8 men and 7 women) and a mean age of 34 years old (age range of 23-50 years old) were enrolled in this study. IM gel 0.05% was applied carefully on the AGWs every two weeks for a maximum of three cycles. The complete clearance rate and recurrence rate were assessed 1 week and 3 months after the last treatment, respectively. Safety was assessed by the occurrence of local skin reaction and the severity of pain was evaluated using the 10-point Visual Analogue Scale. Initially, the AGWs were cleared completely in 10 (66%) patients while 4 (40%) and all of (100%) the patients experienced a recurrence in the 3- and 12-months follow-ups, respectively. All the 15 patients experienced some degrees of pain and local adverse reactions. The mean score of the reported pain was equal to 5.87 ± 2.39. The use of IM gel 0.05% in the treatment of the difficult-to-treat cases of AGWs is associated with a high recurrence rate despite the initial rapid and effective clearance of the lesions. Also, the high level of local adverse reactions and severe pain are other prohibitive factors in the treatment of recalcitrant AGWs with the IM.

Authors+Show Affiliations

Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32602636

Citation

Shahidi Dadras, Mohammad, et al. "Ingenol Mebutate for the Management of Cryotherapy-resistant Anogenital Warts." Dermatologic Therapy, 2020, pp. e13937.
Shahidi Dadras M, Hoormand M, Bizaval Z, et al. Ingenol mebutate for the management of cryotherapy-resistant anogenital warts. Dermatol Ther. 2020.
Shahidi Dadras, M., Hoormand, M., Bizaval, Z., & Mozafari, N. (2020). Ingenol mebutate for the management of cryotherapy-resistant anogenital warts. Dermatologic Therapy, e13937. https://doi.org/10.1111/dth.13937
Shahidi Dadras M, et al. Ingenol Mebutate for the Management of Cryotherapy-resistant Anogenital Warts. Dermatol Ther. 2020 Jun 30;e13937. PubMed PMID: 32602636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ingenol mebutate for the management of cryotherapy-resistant anogenital warts. AU - Shahidi Dadras,Mohammad, AU - Hoormand,Mahmood, AU - Bizaval,Zeinab, AU - Mozafari,Nikoo, Y1 - 2020/06/30/ PY - 2020/04/06/received PY - 2020/06/17/revised PY - 2020/06/26/accepted PY - 2020/7/1/pubmed PY - 2020/7/1/medline PY - 2020/7/1/entrez KW - anogenital warts KW - condylomata acuminate KW - cryotherapy KW - ingenol mebutate SP - e13937 EP - e13937 JF - Dermatologic therapy JO - Dermatol Ther N2 - Ingenol mebutate (IM), as an active compound, is derived from the sap of the Euphorbia peplus, which is an FDA-approved plant for the treatment of actinic keratosis. Some reports have demonstrated that the IM gel 0.05% is safe and effective in the treatment of external anogenital warts (AGWs) but the efficacy of the drug on the recalcitrant AGWs is not clear. This article assesses the efficacy and safety of the IM gel 0.05% for cryotherapy -resistant AGWs. Totally, 15 cryotherapy-resistant patients with AGWs (including 8 men and 7 women) and a mean age of 34 years old (age range of 23-50 years old) were enrolled in this study. IM gel 0.05% was applied carefully on the AGWs every two weeks for a maximum of three cycles. The complete clearance rate and recurrence rate were assessed 1 week and 3 months after the last treatment, respectively. Safety was assessed by the occurrence of local skin reaction and the severity of pain was evaluated using the 10-point Visual Analogue Scale. Initially, the AGWs were cleared completely in 10 (66%) patients while 4 (40%) and all of (100%) the patients experienced a recurrence in the 3- and 12-months follow-ups, respectively. All the 15 patients experienced some degrees of pain and local adverse reactions. The mean score of the reported pain was equal to 5.87 ± 2.39. The use of IM gel 0.05% in the treatment of the difficult-to-treat cases of AGWs is associated with a high recurrence rate despite the initial rapid and effective clearance of the lesions. Also, the high level of local adverse reactions and severe pain are other prohibitive factors in the treatment of recalcitrant AGWs with the IM. SN - 1529-8019 UR - https://www.unboundmedicine.com/medline/citation/32602636/Ingenol_mebutate_for_the_management_of_cryotherapy-resistant_anogenital_warts L2 - https://doi.org/10.1111/dth.13937 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.